Hemp & Cannabidiol UK All articles
Health & Evidence

Absorption, Not Adjectives: A UK Reader's Framework for CBD Bioavailability Claims

Hemp & Cannabidiol UK
Absorption, Not Adjectives: A UK Reader's Framework for CBD Bioavailability Claims

Photo: CBD oil droplets emulsion laboratory science close up blue light, via centralvalley.co.uk

The word that does a lot of work

Bioavailability sounds precise. In pharmacology, it refers to the proportion of a dose that reaches the systemic circulation unchanged, and it is usually expressed alongside measures such as peak plasma concentration and the area under the concentration-time curve. In CBD marketing, the same word is often used more loosely, as a shorthand for 'absorbed better' or 'works faster'. Those may be reasonable hopes, but they are not the same as a demonstrated pharmacokinetic difference.

For a UK shopper, the practical question is not whether a product uses an impressive delivery term. It is whether the brand can explain what was measured, in whom, against what comparator, and whether the result is relevant to the product being sold.

What bioavailability actually measures

When CBD is swallowed in an oil or capsule, it passes through the gut and then the liver before reaching the bloodstream. This first-pass metabolism is one reason why oral CBD doses and plasma levels do not map neatly onto one another. Absorption can also be affected by food, by the formulation, by the dose and by individual variation.

A bioavailability study therefore needs a clear design. Was it conducted in humans or animals? Was it a single dose or repeated dosing? Was the product taken fasting or with food? What was the comparator: a simple oil, a different emulsion, or an intravenous dose? What was measured: total CBD in plasma, free CBD, or a metabolite? Without these details, a headline figure such as 'up to five times more absorbable' is difficult to interpret and almost impossible to apply to a different product.

The vocabulary, translated

Oil-based products usually dissolve CBD in a carrier such as medium-chain triglycerides. This is the traditional format, and it remains the benchmark against which newer claims are often made.

Emulsions disperse oil droplets in water. A well-made emulsion can present CBD in smaller droplets, increasing the surface area available for digestion and absorption. That is a plausible mechanism, though the size of the effect depends on the formulation and the evidence.

Nanoemulsions use much smaller droplets, often measured in nanometres. Smaller droplets may improve absorption, but 'nano' is a description of particle size, not a guarantee of clinical superiority. The long-term safety profile of some novel delivery systems is also less established than that of conventional oils, which is a reason for measured enthusiasm rather than alarm.

Liposomal products wrap cannabinoids in lipid bilayers. The concept is familiar from other supplements, but the quality of evidence varies widely between products, and a liposomal label does not by itself demonstrate better delivery.

Water-soluble is the least precise term of the group. CBD is lipophilic and not truly water-soluble in the ordinary sense. What brands usually mean is that the CBD has been dispersed or emulsified in a water-compatible system. That can be a legitimate formulation choice, but the phrase should be read as marketing shorthand rather than a chemical fact.

Where the evidence is thin

There is genuine research on CBD formulation and absorption, including work on self-emulsifying systems and particle-size reduction. Some studies report faster or higher plasma exposure for particular formulations. But the evidence base is uneven. Studies are often small, sometimes industry-funded, and frequently conducted with a single product that is not the one on the shelf.

A further complication is that faster absorption is not the same as a better outcome. A product that produces a sharp peak may be desirable for some purposes and less desirable for others. For most UK consumers using CBD as a wellness product, the relevant question is whether a formulation helps them take a consistent dose at a consistent cost, not whether it wins a pharmacokinetic race.

A five-question framework

When a brand makes a bioavailability claim, five questions will separate substance from slogan.

  1. What exactly is claimed? 'Enhanced absorption' is vague. 'A 2.5-fold increase in AUC compared with the same dose in MCT oil in a randomised crossover study of 24 adults' is specific.
  2. Is there a study, and is it published? A peer-reviewed paper is stronger than an internal summary. A conference abstract is weaker than a full paper. No document at all is weaker still.
  3. Does the study match the product? A result for one emulsion does not automatically transfer to another, even if both use the same delivery terminology.
  4. What was the comparator? A comparison with water or a placebo tells you less than a comparison with a conventional oil at the same dose.
  5. What does it mean for dose and cost? If a product is twice as absorbable but four times the price per milligram, the shopper may still be worse off. The relevant calculation is cost per milligram of CBD actually delivered, not cost per millilitre of liquid.

Price, dose and the comparison trap

Premium delivery systems can legitimately cost more to manufacture. The difficulty is that price is often used as a proxy for evidence. A high price may reflect research, quality control and formulation work; it may also reflect packaging and positioning. The only way to tell is to ask for the documentation.

It is also worth remembering that dose remains a major variable. A well-absorbed low dose and a poorly absorbed high dose may produce similar exposure. Consumers comparing products should look at the total cannabinoid content, the serving size and the cost per milligram before assuming that a higher price buys a better experience.

A sensible conclusion

Delivery science is a real and developing field, and some formulation work is genuinely interesting. But the vocabulary has run ahead of the evidence in parts of the market. A calm approach is to treat bioavailability claims as questions rather than promises: ask what was measured, in what product, against what comparator, and at what cost per milligram.

For most people, a clearly labelled product with a batch-specific certificate of analysis, a sensible dose and a price they can sustain is a better starting point than an unfamiliar delivery system with an impressive adjective. Absorption matters. So does knowing what you are actually absorbing.

All Articles

Related Articles

Beyond the Top Cupboard: Rethinking How UK Households Store CBD

Beyond the Top Cupboard: Rethinking How UK Households Store CBD

The Regulator's Inbox: A Practical UK Guide to Logging CBD Adverse Reactions

The Regulator's Inbox: A Practical UK Guide to Logging CBD Adverse Reactions

A Second Patient at the Counter: CBD, Prescription Medicines and the UK Shopper

A Second Patient at the Counter: CBD, Prescription Medicines and the UK Shopper